G D Searle: Clinical Trials

4 completed. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 3
Phase 1	1	Completed 1

Follow G D Searle: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex Butyldeoxynojirimycin - HIV Infections	Phase 1	Completed	G D Searle	48		2005-06-24
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV Glycovir, Zidovudine - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	210		2021-10-28
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible) Butyldeoxynojirimycin, Zidovudine - HIV Infections	Phase 2	Completed	G D Searle			2005-06-24
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3 Butyldeoxynojirimycin, Zidovudine - HIV Infections	Phase 2	Completed	G D Searle	120		2005-06-24

Conditions studied

HIV Infections (4)  ·  AIDS-Related Complex (2)  ·  Acquired Immunodeficiency Syndrome (2)

Interventions

Zidovudine (3)  ·  miglustat (3)  ·  glycovir (1)

Countries

United States (4)

Top investigators

Fischl MA (1)  ·  Saag M (1)